Abstract
Inflammation is postulated to play an important role in ovarian carcinogenesis. Prostaglandin endoperoxide synthase 2 (PTGS2) is responsible for the conversion of arachidonic acid to prostaglandins in response to inflammation. In a pooled analysis of two population-based studies, the Hawaii Ovarian Cancer Case–Control Study and the New England Case–Control Study, including 1,025 women with invasive ovarian carcinoma and 1,687 cancer-free controls, the association of ovarian cancer risk with the PTGS2 rs5275 polymorphism and the use of nonsteroidal antiinflammatory drugs (NSAIDs) were examined. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. In the pooled analysis, the CC genotype was associated with a reduced risk of nonserous ovarian carcinoma (OR = 0.66; CI: 0.44–0.98). In addition, the lowest risk was observed among carriers of the CC genotype who were users of only nonaspirin NSAIDs (OR = 0.43; CI:0.20–0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies.
Similar content being viewed by others
References
Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288
Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163
Espey LL (1994) Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 50(2):233–238
Richards JS, Russell DL, Ochsner S, Espey LL (2002) Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 64:69–92
Ames BN, Shigenaga MK, Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 90(17):7915–7922
Hofseth LJ, Ying L (2006) Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochim Biophys Acta 1765(1):74–84
Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17(1):104–107
Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19(2):435–442
Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D (1993) Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 55(3):408–410
Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351(9096):104–107
Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33(6):682–687
Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108(2):281–286
Tavani A, Gallus S, La VC, Conti E, Montella M, Franceschi S (2000) Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 11(9):1171–1173
Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL (2008) Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 167(12):1430–1437
Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169(11):1378–1387
Crew KD, Neugut AI (2006) Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol 18(1):71–75
Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271(52):33157–33160
DuBois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12(12):1063–1073
Landen CN Jr, Mathur SP, Richardson MS, Creasman WT (2003) Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188(5):1174–1176
Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K (2003) Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22(1):99–105
Khalifeh I, Munkarah AR, Lonardo F et al (2004) Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 23(2):162–169
Li S, Miner K, Fannin R, Carl BJ, Davis BJ (2004) Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 92(2):622–627
Cok SJ, Morrison AR (2001) The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276(25):23179–23185
Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM (2000) Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 275(16):11750–11757
Yang H, Gu J, Lin X et al (2008) Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236–2244
Cho KR, Shih I (2009) Ovarian cancer. Annu Rev Pathol 4:287–313
Mok SC, Kwong J, Welch WR et al (2007) Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5–6):367–376
Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I (2009) Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 14(5):383–391
Chiaffarino F, Parazzini F, Bosetti C et al (2007) Risk factors for ovarian cancer histotypes. Eur J Cancer 43(7):1208–1213
Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53
Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD (2008) Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. Adv Exp Med Biol 622:53–67
Terry KL, De VI, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65(13):5974–5981
Tung KH, Goodman MT, Wu AH et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638
Backlund MG, Mann JR, DuBois RN (2005) Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69(Suppl 1):28–32
Thun MJ (2000) Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology 11(4):371–374
Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55
Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101(10):1206–1218
Cuzick J, Otto F, Baron JA et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507
Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91(11):916–932
Denkert C, Kobel M, Pest S et al (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160(3):893–903
Munkarah A, Ali-Fehmi R (2005) COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 17(1):49–53
Ozel E, Pestereli HE, Simsek T, Erdogan G, Karaveli FS (2006) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters? Int J Gynecol Cancer 16(2):549–555
Uddin S, Ahmed M, Hussain A et al (2010) Cyclooxygenase-2 inhibition inhibits PI3 K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126(2):382–394
Seo SS, Song YS, Kang DH et al (2004) Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92(3):927–935
Acknowledgments
The authors thank the physicians, administrators, and cancer registrars at the following institutions for their support of this study: Castle Memorial Hospital, Kaiser Foundation Hospital, Kapiolani Medical Center for Women and Children, Kuakini Medical Center, Queen’s Medical Center, Straub Clinic and Hospital, St Francis Hospital, Tripler Army Hospital, and Wahiawa General Hospital. We would also like to thank the NECC participants and their physicians. We are grateful to the family and friends of Kathryn Sladek Smith for their generous support of Ovarian Cancer Association Consortium through their donations to the Ovarian Cancer Research Fund. We thank Annette Lum-Jones and Ann Seifried for their assistance with genotyping. The findings and conclusions of this study do not necessarily represent the views of these physicians and institutions.
Financial Support
US Public Health Service grants R01-CA-58598, R01-CA-54419, P50-CA-105009, and contracts N01-CN-55424 and N01-PC-67001 from the National Cancer Institute, NIH, Department of Health and Human Services.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lurie, G., Terry, K.L., Wilkens, L.R. et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 21, 1731–1741 (2010). https://doi.org/10.1007/s10552-010-9602-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-010-9602-x